
Changchun Deng, MD, PhD, discusses the evolution of Hodgkin lymphoma management following data readouts at the 2023 ASH Annual Meeting.

Your AI-Trained Oncology Knowledge Connection!


Changchun Deng, MD, PhD, discusses the evolution of Hodgkin lymphoma management following data readouts at the 2023 ASH Annual Meeting.

Changchun Deng, MD, PhD, discusses considerations for covalent BTK inhibitors vs venetoclax-based treatment regimens for chronic lymphocytic leukemia.

Changchun Deng, MD, PhD, discusses the mechanism of action and advantageous features of pirtobrutinib for patients with chronic lymphocytic leukemia.